Qiagen N.V. (QGEN) Q1 FY26 earnings call

Qiagen reported mixed Q1 FY26 results, with adjusted EPS meeting expectations due to disciplined execution, despite sales falling short of targets. The primary drag was a significant decline in QuantiFERON immigration testing demand, alongside ongoing caution from U.S. Life Sciences customers. Management has proactively reset its full-year outlook to reflect these headwinds but maintains confidence in a stronger second half driven by new product launches and sequential improvements in key areas.